Provided by Tiger Trade Technology Pte. Ltd.

vTv Therapeutics

33.89
+0.63501.91%
Volume:18.00K
Turnover:610.39K
Market Cap:133.46M
PE:-32.10
High:34.66
Open:33.42
Low:32.87
Close:33.26
52wk High:44.00
52wk Low:15.27
Shares:3.94M
Float Shares:2.42M
Volume Ratio:0.41
T/O Rate:0.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0558
EPS(LYR):-3.2022
ROE:-15.80%
ROA:-10.14%
PB:6.26
PE(LYR):-10.58

Loading ...

vTv Therapeutics grants 39,500 inducement stock options at $32 exercise price

Reuters
·
May 09

vTv Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 09

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 09

vTv Therapeutics to present at H.C. Wainwright BioConnect investor conference

Reuters
·
May 07

vTv Therapeutics to Participate in Upcoming May Investor Conferences

GlobeNewswire
·
May 07

vTv Therapeutics announces annual shareholder meeting

Reuters
·
Apr 29

vTv Therapeutics grants 4,000 inducement stock options at USD 39.54 per share

Reuters
·
Apr 08

vTv Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Apr 08

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 08

Analysts’ Opinions Are Mixed on These Healthcare Stocks: vTv Therapeutics (VTVT) and CSPC Pharmaceutical Group (OtherCHJTF)

TIPRANKS
·
Mar 27

vTv Therapeutics to Participate in the 38th Annual ROTH Conference

GlobeNewswire
·
Mar 16

Evercore ISI Initiates vTv Therapeutics at Outperform With $44 Price Target

MT Newswires Live
·
Mar 12

vTv Therapeutics Price Target Maintained With a $49.00/Share by BTIG

Dow Jones
·
Mar 12

vTv Therapeutics price target raised to $55 from $35 at Alliance Global

TIPRANKS
·
Mar 11

Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Sarepta Therapeutics (SRPT) and vTv Therapeutics (VTVT)

TIPRANKS
·
Mar 11

vTv Therapeutics Inc : Alliance Global Partners Raises Target Price to $55 From $35

THOMSON REUTERS
·
Mar 11

Buy Rating on vTv Therapeutics Underpinned by Late-Stage T1D Catalyst, Strengthened Balance Sheet, and Diversified Partnership-Driven Upside

TIPRANKS
·
Mar 11

vTv Therapeutics Highlights Cadisegliatin Phase 3 and Cash Runway

TIPRANKS
·
Mar 11

vTv Therapeutics reports Q4 EPS (58c), consensus ($1.09)

TIPRANKS
·
Mar 11

vTv Therapeutics Q4 net loss widens on higher expenses

Reuters
·
Mar 11